aripiprazole (Livzon Microsphere Technology)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Namearipiprazole (Livzon Microsphere Technology)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D2 receptor partial agonistsSerotonin 1a (5-HT1a) receptor partial agonistsSerotonin 2a (5-HT2a) receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorSerotonin 1a (5-HT1a) receptorDopamine D2 receptor
Therapy Area/IndicationsSchizophreniaDissociative Identity Disorder
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLivzon Pharmaceutical Group Inc
China Registration ClassN/A

Develop Information

Active CompaniesLivzon Pharmaceutical Group Inc
Inactive CompaniesN/A
Active IndicationsSchizophrenia
Inactive IndicationsDissociative Identity Disorder

Other Information

ATC CodeN/A
Related LinksN/A